Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO Debt Repayment

Cash used to repay borrowings during the period.

Novo Nordisk A/SNYSE: NVO

Debt Repayment · Q2 FY2026 · quarter ended Jun 2026

Debt repayment declines year over year

Q2 FY2026 debt repayment of DKK 7.34B (cash outflow) fell 62.6% year over year, behind the -8.0% change in trailing-twelve-month debt repayment.

Context

  • Debt repayment amounted to 8.0% of revenue in FY2025, down 17.2 pp from a year earlier.
  • Debt repayment increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -62.6% toward the trailing-twelve-month pace of -8.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-DKK 7.34B-149.8% QoQ
Last fiscal yearDec 2025
DKK 24.74B-66.1% YoY
LTMJun 2026
DKK 36.44B-8.0% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-62.6%——
1 year-66.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

DKK · from the cash flow

Latest · FY2025
24.74B DKK
Year-over-year change
-66.1%
4-year CAGR
+12.5%

Debt Repayment vs competitors

How NVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -8.0% is the 8th highest of 9, against a peer median of +125.9%.
  • Debt repayment amounts to 11.1% of revenue for NVO, versus a peer median of 3.0%.
NVO Competitors
Debt Repayment for NVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 36.44B DKK-8.0%—11.1%
MRKMerck & Co., Inc.LTM Jun 2026$18.64B USD+723.0%—28.1%
LLYEli Lilly and CompanyLTM Jun 2026$15.22B USD+47.0%—19.1%
SNYSanofiLTM Jun 2026€3.21B EUR——6.6%
PFEPfizer Inc.LTM Jun 2026$1.78B USD+121.9%-72.4%2.8%
AMGNAmgen Inc.LTM Jun 2026$1.32B USD+157.5%—3.5%
GSKGSK plcLTM Jun 2026£998.88M GBP+753.7%—3.0%
AZNAstraZeneca PLCLTM Sep 2026$793.27M USD+8.5%+11.3%1.3%
JNJJohnson & JohnsonLTM Sep 2026$787M USD-108.7%+8.9%0.8%
ABBVAbbVie Inc.LTM Jun 2026$418M USD+130.0%-70.3%0.6%
Peer median (excluding NVO) —+125.9%-30.7%3.0%

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income47.76B55.53B83.68B100.99B102.43B
Depreciation & Amortization6.03B7.36B9.41B19.11B21.98B
Deferred Income Tax11.32B13.54B20.99B26.2B28.11B
Stock-Based Compensation1.04B1.54B2.15B2.29B0
Change in Working Capital(8.66B)(5.54B)(12.25B)2.59B3.74B
Accounts Receivables(12.91B)(10.82B)(14.21B)(14.31B)0
Inventory(1.09B)(4.77B)(7.42B)(9.04B)0
Accounts Payables3.15B6.72B10.02B3.24B0
Other Working Capital2.19B3.34B(631M)22.7B3.74B
Other Non-Cash Items(2.49B)6.46B4.92B(30.21B)(37.16B)
Operating Cash Flow55B78.89B108.91B120.97B119.1B
Capital Expenditures(7.39B)(14.75B)(38.9B)(51.31B)(90.11B)
Acquisitions (Net)(18.28B)(7.08B)0(82.16B)1B
Purchases of Investments(7.11B)(9.74B)(13.29B)(19.81B)(723M)
Sales of Investments1.17B6.65B8.29B24.39B10.67B
Other Investing Activities4M(2.61B)(13.09B)(4.15B)(29.97B)
Investing Cash Flow(31.61B)(24.92B)(43.89B)(128.9B)(79.16B)
Debt Repayment15.47B(2.41B)(1.47B)73.06B24.74B
Common Stock Issued00000
Common Stock Repurchased(19.45B)(24.09B)(29.92B)(20.18B)(1.39B)
Dividends Paid(21.52B)(25.3B)(31.77B)(44.14B)(51.76B)
Other Financing Activities00000
Financing Cash Flow(25.49B)(51.8B)(63.16B)8.74B(28.41B)
Effect of Forex Changes591M(238M)(119M)455M(727M)
Net Change in Cash(1.51B)1.93B1.74B1.26B10.81B
Free Cash Flow47.62B64.13B70.01B69.66B28.99B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.